作者
Nitin Jain,Michael J. Keating,Philip A. Thompson,Alessandra Ferrajoli,Jan A. Burger,Gautam Borthakur,Koichi Takahashi,Zeev Estrov,Nathan Fowler,Tapan M. Kadia,Marina Konopleva,Yesid Alvarado,Musa Yılmaz,Courtney D. DiNardo,Prithviraj Bose,Maro Ohanian,Naveen Pemmaraju,Elias Jabbour,Koji Sasaki,Rashmi Kanagal‐Shamanna,Keyur P. Patel,Jeffrey L. Jorgensen,Naveen Garg,Xuemei Wang,Katrina Sondermann,Nichole Cruz,Chongjuan Wei,Ana Ayala,William Plunkett,Hagop M. Kantarjian,Varsha Gandhi,William G. Wierda
摘要
Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination.
PDF的下载单位、IP信息已删除
(2025-6-4)
科研通AI6.2
蓝天
pluto
糟糕的铁锤
Criminology34
稳重的蛟凤
呜呜呜
殷勤的紫槐
源铭
专注的问寒
GingerF
乐空思
轨迹
光亮海云
无极微光
cc2004bj
lizishu
YYYHHH
Twonej
stiger
Mic
luo
yznfly
沈清酌
皖公网安备34019202002308
